Axsome expects to address the concerns in the letter and plans to resubmit AXS-07. The MoSEIC meloxicam-rizatriptan combination significantly reduced migraine symptoms and pain compared with placebo and both active agents in a pair of phase 3 trials.
The professor of neurology at the University of Basel provided insight on a new methodology that allows depiction of patient profiles from baseline characteristics and their associations with individual outcomes. [WATCH NOW: 5 minutes]
Here's what is coming soon to NeurologyLive®.
The neurologist at Christus St. Vincent Health System provided insight on the desperate need for new medications for both motor and nonmotor symptoms of Parkinson disease. [WATCH TIME: 3 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.
Vincent Martin, MD, president of the National Headache Foundation, discussed the MOTS trial, a non-inferiority study aimed at understanding treatment strategies with preventives for chronic migraine.
Baseline neurofilament light levels were associated with future disability progression and degree of brain atrophy regardless of the presence or absence of acute disease activity.
Neurology News Network for the week ending April 30, 2022. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 29, 2022.
Shurjal Baxi, MD, MPH, the senior vice president of Clinical and Scientific Solutions at Verana Health, shared her perspective on the AAN’s Axon Registry and how quality data collection can drive improvements in patient care and management.
Peter J. McAllister, MD, FAAN, medical director and chief medical officer, New England Center for Neurology and Headache, offered his insight into data from the phase 2 STEMTRA trial in TBI and the trends he’s observed in the field of regenerative medicine.
A best-case analysis indicated that, for amyloid-positive patients diagnosed with MCI due to AD or mild AD dementia, lecanemab plus standard of care provided an additional gain of 0.75 in quality-adjusted life years.
Pitolisant, an agent that originally received FDA-approval in 2019 to treat excessive daytime sleepiness in narcolepsy, will have efficacy and safety evaluated in a cohort of 200 patients with idiopathic hypersomnia.
The approval is supported by phase 3 data which showed statistically significant differences on MG-ADL and QMG scores relative to placebo following 26 weeks of treatment.
The assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute provided insight on the areas of focus during Parkinson Awareness Month. [WATCH TIME: 3 minutes]
Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.
The difference in inflammatory disease activity between men and women faded after the age of 50 years, whereas the sex difference in the neurodegenerative component of MS became apparent after the age of 45 years and deepened with older age.
Patients who switched from a twice-nightly stable regimen of Xyrem or Xywav to once-nightly FT218 reported that they preferred the new dosing schedule, along with challenges in adherence to twice-nightly dosing.
After 1 year of follow-up, the cumulative incidences of recurrent intracerebral hemorrhage, cerebrovascular ischemic events, and all-cause death were 2.8%, 3.2%, and 22.0%, respectively, for those initiating or resuming oral anticoagulant therapy.
Only 17% of patients who received 1 g/kg of intravenous immunoglobulin every 4 weeks or more experienced disease relapse compared with 50% of those treated with lower or less frequent dosing.
The neurologist at Christus St. Vincent Health System provided commentary on the importance of emphasizing social connectedness following diagnosis of Parkinson disease, along with the signs to look for in social isolation. [WATCH TIME: 4 minutes]
The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the phenomenon behind reflex tears and whether they can serve as a valuable biomarker for Parkinson disease.
Following respective improvements in odds of good and poor outcomes, investigators concluded that the addition of mechanical thrombectomy should be considered over best medical management practices alone.
In the main matched analysis, associated noted before Parkinson disease diagnosis were motor (up to 10 years) and cognitive (up to 5 years) symptoms.
Following an NCD that will allow for Medicare coverage of the therapy only in NIH- and FDA-approved studies and trials, Biogen has pulled its application to the European Medicines Agency for aducanumab treatment in Alzheimer disease.
The neurologist and assistant professor at the University of Toronto discussed why elevating the voices of patients and caregivers is important to understanding and treating an individual with Alzheimer disease. [WATCH TIME: 3 minutes]
Those treated with siponimod (Mayzent; Novartis) for 5 or more years had significant reductions in 6-month disability and cognitive processing speed compared with patients who switched from placebo.
After readjusting baseline to month 12, more patients with relapsing multiple sclerosis on continuous ozanimod achieved NEDA-3 and NEDA-4 status than those on interferon ß-1a.
Despite a low percentage of patients missing work time due to their condition, a higher percentage reported impairment while working, overall work impairment, and activity impairment.
Robert Zivadinov, MD, PhD, discusses the design of a novel comparative study assessing the effect of siponimod (Mayzent; Novartis) and ocrelizumab (Ocrevus; Genentech) on microglia and astrocytes in patients with SPMS.
